Resources
125 Results (showing 31 - 40)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 2/28/2023 (updated 3/27/2024)
Harm in Behavioral Health: The Ethical Necessity for Multicultural Practices in Behavioral Health Programs webinar training material.
Posted 3/21/2023 (updated 3/27/2024)
Training materials A Stimulating Talk
Posted 3/7/2023 (updated 3/27/2024)
Training material Pre-Addiction: Research Needed to Evaluate its Public Health Value
Posted 3/29/2023 (updated 3/27/2024)
The study has identified inherited genetic markers that are commonly inherited across addiction disorders, regardless of the substance being used. It also reinforces the role of the dopamine system within substance use disorders. This may help to further understand and implement personalized interventions for people with substance use disorders by taking into account a person's biology, environment, and lived experience.
Posted 5/31/2022 (updated 3/27/2024)
With facts and figures about health status, behavioral risk factors, mortality, and access to care, the resource aims to inform rural health policy for four states – Arizona, California, New Mexico, and Texas – along the U.S. southern border. The chartbook is a collaboration between the FORHP-supported Rural & Minority Health Research Center and the National Rural Health Association.
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses opioid-related overdoses. This campaign expands on the Ad Council's The Real Deal on Fentanyl platform.
Posted 11/1/2022 (updated 3/27/2024)
Racial/ethnic minorities have experienced disproportionate opioid-related overdose death rates in recent years. In this context, inequities were examined in community-based naloxone access across racial/ethnic groups in Massachusetts.
Posted 6/6/2022 (updated 3/27/2024)
The goal of the training was to develop knowledge and skills to discuss infectious disease/sexual health concerns and provide health promotion support in OUD settings.
Posted 6/7/2022 (updated 3/27/2024)
We began with a critical examination of the history of family separation in the US to lay the groundwork for a discussion of both provider and patient trust and mistrust. The stigma and discrimination that pregnant, postpartum, and parenting people with substance use disorder was explored. We concluded with concrete suggestions to improve provider wellness, child development, and community cohesion.